Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

The Journal of Managed Care & Specialty Pharmacy is a premier publication in the realm of health policy and pharmaceutical science, dedicated to enhancing the understanding and practices surrounding managed care systems and specialty medications. Published by ACAD MANAGED CARE PHARMACY, this journal boasts an impressive Q1 ranking in both Pharmaceutical Science and Pharmacy, underscoring its significance in advancing professional discourse and research in these critical areas. With a focus on innovative care strategies and patient-centered approaches, it aims to share impactful research, reviews, and opinions that shape the future of health policy and pharmaceutical practices. The journal is available in an open access format, ensuring that vital information is universally accessible to researchers, practitioners, and policymakers alike. With its inception in 2014 and an ongoing commitment to excellence through 2024, the journal is firmly established as a leading resource within its field, making it essential reading for professionals dedicated to improving managed care and specialty pharmacy solutions.

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.